Summary & Overview

Cardiac Congenital and Valvular Disorders without MCC: Inpatient Reimbursement Overview

DRG 307 encompasses inpatient stays for cardiac congenital and valvular disorders without Major Complication or Comorbidity, capturing cases managed without severe concurrent conditions. Correct grouping is important for Medicare inpatient reimbursement because it determines payment level, reflects expected resource use, and hinges on documentation and coding of comorbidities and procedures.

Cardiac Congenital and Valvular DisordersDRG Cardiac Congenital and Valvular Disorders without MCCDRG 307Diagnosis-Related GroupInpatient ReimbursementMedicareCardiologyCardiac SurgeryValvular DiseaseCongenital Heart Disease

DRG 307 Overview

DRG 307 covers inpatient admissions for cardiac congenital and valvular disorders without Major Complication or Comorbidity and includes procedures and diagnoses related to congenital heart defects and valvular disease managed without severe concurrent conditions. This Diagnosis-Related Group groups patients by clinical similarity and resource use to determine Medicare payment for the episode of care. It matters because classification into this Diagnosis-Related Group affects payment rates, length-of-stay considerations, and billing documentation requirements for Centers for Medicare & Medicaid Services reimbursement. Accurate coding and capture of comorbidities influence whether an admission qualifies for this Diagnosis-Related Group versus a higher-paying group with Major Complication or Comorbidity.

Clinical Trials

Perioperative and procedural intervention trials evaluating timing and techniques for valve repair versus replacement in non-MCC valvular disease: These studies enroll adult and pediatric patients with congenital valvular lesions or acquired valvular disease requiring admission but without major complications, comparing specific surgical approaches (minimally invasive vs open, repair techniques) or perioperative management protocols (anticoagulation strategies, myocardial protection). The objective is to determine which procedural choices and intraoperative care pathways reduce length of stay, readmissions, and complications; findings inform surgeons and hospital administrators about resource use, expected recovery trajectories, and short-term reimbursement implications for DRG 307 admissions.
Comparative effectiveness and medical management trials for conservative therapy in symptomatic but non-MCC valvular and congenital cardiac disorders: These trials focus on patients admitted for heart failure symptoms, arrhythmia management, or symptomatic congenital lesions who are managed non-surgically or are optimized before elective intervention, comparing different medical regimens, timing of intervention, or device-based monitoring strategies. The goal is to identify which inpatient management approaches best stabilize patients, reduce conversion to higher-acuity care, and minimize subsequent admissions, providing payers and clinicians evidence to guide utilization, length of stay, and case-mix adjustments under this DRG.
Post-discharge outcomes, care-transition, and long-term functional status studies tracking readmissions and quality-of-life after hospitalization for congenital or valvular disorders without major complications: These observational or randomized care-management trials enroll patients discharged after index admission to evaluate transitional care interventions (structured follow-up, remote monitoring, rehabilitation) and measure 30- and 90-day readmission rates, functional recovery, and outpatient resource use. Such research is relevant because improved discharge planning and outpatient management can lower readmissions and downstream costs, influence bundled payment strategies, and help hospitals and payers optimize post-acute resource allocation for patients categorized in DRG 307.

Related Codes

252-OTHER-VASCULAR-PROCEDURES-WITH-MCC

Other Vascular Procedures with MCC: Inpatient Reimbursement Overview

288-ACUTE-AND-SUBACUTE-ENDOCARDITIS-WITH-MCC

Acute and Subacute Endocarditis with MCC: Inpatient Reimbursement Overview

272-OTHER-MAJOR-CARDIOVASCULAR-PROCEDURES-WITHOUT-CC-MCC

Other Major Cardiovascular Procedures without CC/MCC: Inpatient Reimbursement Overview

299-PERIPHERAL-VASCULAR-DISORDERS-WITH-MCC

Peripheral Vascular Disorders with MCC: Inpatient Reimbursement Overview

261-CARDIAC-PACEMAKER-REVISION-EXCEPT-DEVICE-REPLACEMENT-WITH-CC

Cardiac Pacemaker Revision Except Device Replacement with CC: Inpatient Reimbursement Overview

289-ACUTE-AND-SUBACUTE-ENDOCARDITIS-WITH-CC

Acute and Subacute Endocarditis with CC: Inpatient Reimbursement Overview

325-CORONARY-INTRAVASCULAR-LITHOTRIPSY-WITHOUT-INTRALUMINAL-DEVICE

Coronary Intravascular Lithotripsy without Intraluminal Device: Inpatient Reimbursement Overview

281-ACUTE-MYOCARDIAL-INFARCTION-DISCHARGED-ALIVE-WITH-CC

Acute Myocardial Infarction, Discharged Alive with CC: Inpatient Reimbursement Overview

243-PERMANENT-CARDIAC-PACEMAKER-IMPLANT-WITH-CC

Permanent Cardiac Pacemaker Implant with CC: Inpatient Reimbursement Overview

291-HEART-FAILURE-AND-SHOCK-WITH-MCC

Heart Failure and Shock with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.